Poseida Therapeutics Inc

NASDAQ:PSTX   3:59:51 PM EDT
4.30
-0.10 (-2.27%)
Products, Strategic Combinations

Poseida Therapeutics Announces Strategic Global Collaboration With Roche Focused On Allogeneic Car-T Cell Therapies For Hematologic Malignancies

Published: 08/03/2022 12:19 GMT
Poseida Therapeutics Inc (PSTX) - Poseida Therapeutics Announces Strategic Global Collaboration With Roche Focused on Allogeneic Car-t Cell Therapies for Hematologic Malignancies.
Poseida Therapeutics Inc - Poseida Will Receive $110 Million Upfront.
Poseida Therapeutics Inc - Poseida Could Receive Up to $110 Million in Near-term Milestones and Other Payments.
Poseida Therapeutics Inc - Poseida Eligible for Future Development and Commercial Milestones and Tiered Royalty Payments.
Poseida Therapeutics - Roche to Receive Either Exclusive Rights Or Options to Develop and Commercialize a Number of Allogeneic Car-t Programs.
Poseida Therapeutics - Cos to Collaborate in Research Program to Create & Develop Next-generation Features, Improvements for Allogeneic Car-t Therapies.
Poseida Therapeutics Inc - Poseida Will Conduct Phase 1 Studies and Manufacture Clinical Materials Before Transitioning Programs to Roche.
Poseida Therapeutics - Roche to Be Solely Responsible for Late-stage Development, Global Commercialization of All Products Under Agreement.
Poseida Therapeutics - Co Eligible to Receive Research, Development, Launch, Net Sales Milestones, Payments Potentially Up to $6 Billion in Aggregate Value.